Hishida, Manabu
Imaizumi, Takahiro
Menez, Steven
Okazaki, Masaki
Akiyama, Shin’ichi
Kasuga, Hirotake
Ishigami, Junichi
Maruyama, Shoichi
Matsushita, Kunihiro http://orcid.org/0000-0002-7179-718X
Funding for this research was provided by:
Kaikoukai Healthcare Group
Article History
Received: 10 February 2020
Accepted: 29 July 2020
First Online: 20 August 2020
Ethics approval and consent to participate
: In this study, we followed the Japanese Ministry of Health, Labor, and Welfare’s “Outline of ethical guidelines for medical and health research involving human subjects” (issued on December 22, 2014 and revised on February 28, 2017) and the Helsinki Declaration (revised 2013). The study protocol was approved by the Institutional Review Boards of both Nagoya University and the Kaikoukai Healthcare Group (IRB 2014–0422).
: As this was a retrospective cohort study, the need for informed consent was waived by the Institutional Review Boards.
: S.M. is supported by Otsuka Pharmaceutical Co.,Ltd., Chugai Pharmaceutical Co.,Ltd., Pfizer Inc., Kyowa Hakko Kirin Co.,Ltd., MSD KK, Astellas Pharma Inc., Torii Pharmaceutical Co.,Ltd., Daiichi Sankyo Co.,Ltd., Sumitomo Dainippon Pharma Co.,Ltd., Alexion Pharmaceuticals,Inc., and Sanwa Kagaku Kenkyusho Co.,Ltd. None of these companies were involved in study design, data collection, analysis and interpretation of data, writing of the report, or decision to submit the article for publication. K.M. received funding and personal fee from Kyowa Kirin and Fukuda Denshi and personal fee from Akebia outside of the submitted work. All other authors declare no potential conflicts of interest.